Immunoglobulin H-Gamma1_L-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3) And Anti-[Homo Sapiens Dll3 (Delta-Like Ligand 3, Delta Like Canonical Notch Ligand 3)], Bispecific;
Neuroendocrine Carcinoma
Explore 48 assets in Neuroendocrine Carcinoma →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Phanes Therapeutics
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05652686CT.gov A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neuroendocrine Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin H-Gamma1_L-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3) And Anti-[Homo Sapiens Dll3 (Delta-Like Ligand 3, Delta Like Canonical Notch Ligand 3)], Bispecific; (this asset) | Phanes Therapeutics | P1/2 | CCC · 48 |
| Etoposide | National Cancer Institute (NCI) | P2 | B |
| Everolimus | AIO-Studien-gGmbH | P2 | B |
| Tarlatamab | National Cancer Institute (NCI) | P2 | B |
| Pembrolizumab | Ochsner Health System | P2 | B |
| Lurbinectedin | Jazz Pharmaceuticals | P2 | B |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Novartis Pharmaceuticals | P2 | B |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P2 | B |
| Ipilimumab | National Cancer Institute (NCI) | P2 | B |
+42 more in the Neuroendocrine Carcinoma cohort
Other indications for Immunoglobulin H-Gamma1_L-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3) And Anti-[Homo Sapiens Dll3 (Delta-Like Ligand 3, Delta Like Canonical Notch Ligand 3)], Bispecific;
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Large Cell Neuroendocrine Carcinoma | — | P1/2 | CC · 47 |
| Prostate Neuroendocrine Neoplasm | — | P1/2 | CC · 47 |
| Small Cell Lung Carcinoma | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin H-Gamma1_L-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3) And Anti-[Homo Sapiens Dll3 (Delta-Like Ligand 3, Delta Like Canonical Notch Ligand 3)], Bispecific; in Neuroendocrine Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-h-gamma1-l-kappa-anti-homo-sapiens-cd47-cd47-molecule-integrin-associated-protein-iap-mer6-oa3-and-anti-homo-sapiens-dll3-delta-like-ligand-3-delta-like-canonical-notch-ligand-3-bispecific-neuroendocrine-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →